Pathstone Holdings LLC Has $10.05 Million Position in Cencora, Inc. (NYSE:COR)

Pathstone Holdings LLC decreased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 19.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 44,720 shares of the company's stock after selling 10,548 shares during the quarter. Pathstone Holdings LLC's holdings in Cencora were worth $10,048,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC boosted its stake in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the period. Banque Transatlantique SA bought a new position in shares of Cencora during the 4th quarter valued at $29,000. SBI Securities Co. Ltd. bought a new position in shares of Cencora during the 4th quarter valued at $30,000. Householder Group Estate & Retirement Specialist LLC raised its holdings in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Finally, Kentucky Trust Co bought a new position in shares of Cencora during the 4th quarter valued at $33,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This represents a 4.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This trade represents a 24.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock valued at $13,580,967 over the last ninety days. Insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of recent research reports. Robert W. Baird raised their price target on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. UBS Group lifted their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Citigroup boosted their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Bank of America boosted their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $301.18.

Cencora Price Performance

NYSE:COR traded up $2.15 on Monday, reaching $292.37. The stock had a trading volume of 1,553,490 shares, compared to its average volume of 1,544,787. The company has a market capitalization of $56.70 billion, a P/E ratio of 41.59, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $309.35. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a fifty day moving average price of $279.87 and a 200-day moving average price of $255.76.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period in the prior year, the business earned $3.80 earnings per share. Cencora's quarterly revenue was up 10.3% on a year-over-year basis. Research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.